Detalhe da pesquisa
1.
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
Cell
; 184(3): 596-614.e14, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33508232
2.
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Cell
; 183(2): 363-376.e13, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33007267
3.
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Cell
; 183(3): 818-834.e13, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33038342
4.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Cell
; 183(2): 347-362.e24, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064988
5.
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Cell
; 178(4): 933-948.e14, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31398344
6.
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Immunity
; 56(1): 93-106.e6, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574773
7.
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Cell
; 171(6): 1284-1300.e21, 2017 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29195073
8.
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.
Immunity
; 55(1): 56-64.e4, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986342
9.
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7912): 172-179, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545680
10.
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Nature
; 596(7870): 126-132, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290408
11.
Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Immunity
; 47(2): 221-223, 2017 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28813655
12.
Neoantigen-directed immune escape in lung cancer evolution.
Nature
; 567(7749): 479-485, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30894752
13.
TOX is a critical regulator of tumour-specific T cell differentiation.
Nature
; 571(7764): 270-274, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31207604
14.
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Oncologist
; 28(11): 978-985, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589215
15.
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Nature
; 545(7655): 452-456, 2017 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28514453
16.
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Nature
; 551(7681): 517-520, 2017 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29132144
17.
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7914): E5, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641605
18.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Br J Cancer
; 126(6): 889-898, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963703
19.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
20.
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Nature
; 598(7881): E1, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34608287